Health ❯ Healthcare ❯ Clinical Trials

Randomized Controlled Trials

Patient Outcomes Efficacy Studies Phase 3 Trials Meta-Analysis Intervention Studies Meta-analysis TARGET-D Trial Placebo-Controlled Trials DETECT Hep C Trial Crossover Studies

Dual‑Mobility Hip Cups Cut Dislocation Risk by 70% in Large Randomized Trial

Adoption may hinge on an ongoing health‑economic analysis of higher implant costs.

Melatonin Lowers Chronic Musculoskeletal Pain, University of Sydney Analysis Finds

Most IVF Add‑Ons Show Little or No Proven Benefit, Major Lancet Review Finds

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

ctDNA Blood Test Guides Care as Targeted Radiotherapy Improves Control in Early Metastatic Cancer

Evolocumab Cuts First Cardiovascular Events by 31% in High‑Risk Diabetes Without Known Atherosclerosis

Major Lancet Analysis Finds Most Statin Label Side Effects Not Caused by the Drugs

Oral Semaglutide Cuts Serious Heart-Failure Events 22% in Type 2 Diabetes With Heart Failure

First Randomized Trial Finds Telesurgery Matches Local Robotic Surgery Over Long Distances

Apple Watch Screening Quadruples AFib Detection in High-Risk Seniors, EQUAL RCT Finds

Bariatric Surgery’s Long-Term Edge Holds Across Social Vulnerability, ARMMS-T2D Analysis Finds

Yoga Add-On Halves Opioid Withdrawal Time in JAMA Psychiatry Trial

Shenzhuo Formula Improves Kidney Function Versus Irbesartan in 24-Week Diabetes Trial

Anti-Inflammatories Modestly Ease Depression for Patients With Elevated Inflammation, Meta-Analysis Finds

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

EU Medicines Panel Backs Teizeild to Delay Type 1 Diabetes Onset

Real-World Study Finds Semaglutide and Tirzepatide Cut Cardiovascular Risk in Type 2 Diabetes

Personalized Vitamin D Strategy Halves Risk of Repeat Heart Attack in Randomized Trial

JAMA Meta-Analyses at Kidney Week Back Routine SGLT2 Inhibitors Across Kidney Function